Physician profile
Jon E Roberts
NPI 1114933272
$7,017.78
in general payments reported to CMS, 2019-2025
23 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Pediatric Pulmonology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,158 · 2020: $100 · 2021: $377 · 2022: $1,400 · 2023: $543 · 2024: $2,190 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $982.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $2,396.71 | 2019-2025 | Smartvest |
| Pari Respiratory Equipment, INC. | $1,627.50 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $687.79 | 2019-2025 | Fasenra, Tezspire |
| Gilead Sciences, INC. | $440.67 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $356.27 | 2019-2024 | Trikafta |
| Genzyme Corporation | $230.02 | 2021-2022 | |
| Mylan Specialty L.P. | $189.61 | 2021-2022 | |
| Philips North America LLC | $155.02 | 2019-2024 | (O58) Sleep Respiratory Care Und |
| Biogen, INC. | $151.60 | 2022-2023 | Spinraza |
| Baxter Healthcare | $146.86 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $102.60 | 2022 | |
| Biofire Diagnostics, LLC | $90.01 | 2019 | |
| Phadia US INC. | $89.45 | 2019-2022 | |
| Advanced Respiratory, INC | $88.50 | 2019-2021 | |
| Chiesi USA, INC. | $76.82 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $40.04 | 2023-2024 | Relizorb |
| Genentech USA, INC. | $38.45 | 2021-2023 | Actemra |
| Allergan, INC. | $26.59 | 2019 | |
| Abbvie INC. | $23.82 | 2019 | |
| Insmed, INC. | $17.61 | 2019 | |
| Vivus LLC | $15.75 | 2022 | |
| Masimo Corporation | $13.57 | 2022 | |
| Vyaire Medical, INC. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.